2014至2024年美国食品药品监督管理局对肺、睡眠与重症医学新技术审评的临床证据:支持实践采纳的范围综述
该范围综述按PRISMA-ScR指南评估了2014年6月1日至2024年6月30日FDA批准或许可的肺、睡眠与重症医学医疗器械。共790项新器械获批或许可,其中98%通过510k途径,即被认定与已上市产品相似。几乎所有上市前批准器械和一半的De Novo器械使用测量客观临床主要结局而非患者报告主要结局的临床数据获批。结果表明该领域器械审批主要依赖与现有器械的等效性,临床试验一般保留给更高风险的介入性或监测患者状态的器械。
要点
- 2014年6月1日至2024年6月30日共790项肺、睡眠与重症医学新器械获FDA批准或许可。
- 98%的器械通过510k途径获批,即被认定与已上市产品相似。
- 几乎所有上市前批准器械和一半的De Novo器械使用测量客观临床主要结局的临床数据获批,而非患者报告主要结局。
- 该领域器械审批主要依赖与现有器械的等效性,临床试验一般保留给更高风险的介入性或监测类器械。
适用人群与场景
- 肺、睡眠与重症医学领域经FDA批准或许可的医疗器械,评估时间段为2014年6月1日至2024年6月30日。
研究设计与关键结果
- 研究类型:范围综述,按照PRISMA-ScR指南进行。
- 评估对象:2014年6月1日至2024年6月30日期间FDA批准或许可的肺、睡眠与重症医学医疗器械。
- 共790项新器械获FDA批准或许可;其中98%通过510k途径获批,即被认定与已上市产品相似。
- 几乎所有上市前批准器械和一半的De Novo器械使用测量客观临床主要结局而非患者报告主要结局的临床数据获批或分类。
证据类型、等级与局限
- 证据类型:范围综述,遵循PRISMA-ScR指南。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Chest medicine relies extensively on medical devices that comprise medical technology, artificial intelligence, software applications, and digital health; however, a comprehensive assessment of the evidence supporting US Food and Drug Administration (FDA) approval/clearance of these devices is lacking.
RESEARCH QUESTION: What are the trends and evidence related to new medical devices across chest medicine?
STUDY DESIGN AND METHODS: We performed a scoping review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines to assess medical devices approved or cleared by the FDA between June 1, 2014, and June 30, 2024.
RESULTS: A total of 790 new devices were FDA-approved or cleared in the last decade. Of these, 98% of devices were cleared through a 510k pathway, indicating they were deemed similar to other products already on the market. Almost all Premarket Approval devices and one-half of De Novo devices were approved/classified using clinical data that measured objective clinical primary outcomes rather than patient-reported primary outcomes.
INTERPRETATION: Our results show that approval for new medical devices in pulmonary, sleep, and critical care medicine largely depends on establishing equivalence to existing devices. Clinical trials are generally reserved for higher-risk devices that are interventional in nature or monitor the patient's status.
参考来源
- Gardner JT, Busam JA, Shah ED, et al. Clinical Evidence to Support US Food and Drug Administration Review of New Medical Technology in Pulmonary, Sleep, and Critical Care Medicine Between 2014 and 2024: A Scoping Review to Support Adoption in Practice. Chest. 2025. PMID: 41429289. doi:10.1016/j.chest.2025.12.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。